Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Controlled-Current Coulometry: Overview01:27

Controlled-Current Coulometry: Overview

715
Controlled current coulometry, also known as amperostatic coulometry, is a technique used in electrochemical analysis to measure the quantity of a substance through the controlled passage of current. It involves the application of a constant current to an electrochemical cell containing the analyte of interest. As the current flows through the cell, the analyte undergoes a redox reaction at the electrode surface, resulting in a charge transfer. By monitoring the time required for a certain...
715
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.4K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.4K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Characteristics of Practical Op Amps01:16

Characteristics of Practical Op Amps

870
A difference amplifier, a crucial component in numerous electronic devices, ideally amplifies only the difference-mode signal, which is the difference between two input signals. However, in practical circuits, the output voltage depends on both the differential gain and the common-mode gain.
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
870

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma.

Journal of the National Cancer Institute·2026
Same author

Translating ctDNA into cutaneous melanoma care: An international expert survey.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma.

The American Journal of dermatopathology·2026
Same author

ASO Visual Abstract: Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients With Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

Annals of surgical oncology·2026
Same author

Evaluation of Clinical Outcomes and Pattern of Recurrence in Patients with Cutaneous Melanoma and Sentinel Lymph Node Positivity Since the Publication of the MSLT-2 Trial.

Annals of surgical oncology·2026
Same author

ASO Visual Abstract: Prognostic Value of Non-Nodal Regional Metastases in Predicting Sentinel Lymph Node Status in Cutaneous Melanoma: Multicenter Analysis of the Sentinel Lymph Node Working Group Database.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Feb 5, 2026

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
14:56

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb

Published on: September 23, 2018

9.5K

Talimogene laherparepvec: overview, combination therapy and current practices.

Cristina O'Donoghue1,1, Matthew P Doepker1,1, Jonathan S Zager1,1

  • 1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, 33647 USA.

Melanoma Management
|September 8, 2018
PubMed
Summary

Talimogene laherparepvec (T-VEC) is an oncolytic virus therapy for unresectable melanoma. It selectively destroys tumor cells and stimulates an immune response, showing safety and efficacy in clinical trials.

Keywords:
GM-CSFImlygicclinical trialintralesional therapymetastatic melanomaoncolytic therapytalimogene laherparepvec (T-VEC)

More Related Videos

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram
06:14

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram

Published on: October 10, 2025

531
Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI
10:35

Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI

Published on: June 3, 2013

33.3K

Related Experiment Videos

Last Updated: Feb 5, 2026

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
14:56

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb

Published on: September 23, 2018

9.5K
The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram
06:14

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram

Published on: October 10, 2025

531
Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI
10:35

Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI

Published on: June 3, 2013

33.3K

Area of Science:

  • Oncolytic virotherapy
  • Cancer immunotherapy
  • Melanoma treatment

Background:

  • Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus type 1.
  • It is approved for intralesional therapy of unresectable metastatic melanoma.
  • T-VEC selectively replicates in tumor cells, causing lysis and releasing tumor antigens.

Purpose of the Study:

  • To evaluate the safety and efficacy of T-VEC for melanoma.
  • To explore T-VEC's mechanism of action in promoting anti-tumor immunity.
  • To discuss future directions and clinical guideline integration of T-VEC.

Main Methods:

  • Phase I-III clinical trials were conducted to assess T-VEC.
  • Intralesional administration of T-VEC was employed.
  • Mechanism involves tumor cell lysis and granulocyte macrophage colony-stimulating factor (GM-CSF) production.

Main Results:

  • T-VEC demonstrated safety and efficacy in clinical trials.
  • The therapy selectively targets and destroys tumor cells.
  • GM-CSF production may enhance immune-mediated antitumor responses.

Conclusions:

  • Talimogene laherparepvec is an effective oncolytic virus therapy for melanoma.
  • T-VEC is recognized in NCCN guidelines for specific melanoma stages.
  • Combination therapies with T-VEC and systemic immunotherapies are promising future directions.